Selected article for: "primary endpoint and viral load"
Author: Duval, Xavier; van der Werf, Sylvie; Blanchon, Thierry; Mosnier, Anne; Bouscambert-Duchamp, Maude; Tibi, Annick; Enouf, Vincent; Charlois-Ou, Cécile; Vincent, Corine; Andreoletti, Laurent; Tubach, Florence; Lina, Bruno; Mentré, France; Leport, Catherine
Title: Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial
  • Document date: 2010_11_2
    • ID: 19sejitq_13
    Snippet: The primary efficacy endpoint was the proportion of patients with RT-PCR,200 cgeq/ml on day 2 of treatment. Given the viral shedding kinetics in patients with seasonal influenza receiving neuraminidase inhibitors, the day 2 virological endpoint was considered to be best suited to measurement of virological effects [2, 4] . Other endpoints were (1) the decrease of log 10 viral load between days 0 and 2 in the patients with confirmed influenza A on.....
    Document: The primary efficacy endpoint was the proportion of patients with RT-PCR,200 cgeq/ml on day 2 of treatment. Given the viral shedding kinetics in patients with seasonal influenza receiving neuraminidase inhibitors, the day 2 virological endpoint was considered to be best suited to measurement of virological effects [2, 4] . Other endpoints were (1) the decrease of log 10 viral load between days 0 and 2 in the patients with confirmed influenza A on day 0 and available samples both at days 0 and 2; (2) the time to resolution of illness; (3) the number of patients with alleviation of symptoms at the end of treatment (day 5); (4) the symptoms score at the end of treatment; (5) the incidence of secondary complications of influenza such as otitis, bronchitis, sinusitis, pneumonia, and the use of antibiotics; (6) the occurrence of adverse events in all participants having received at least one dose.

    Search related documents:
    Co phrase search for related documents
    • adverse event and dose receive: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • adverse event and efficacy endpoint: 1, 2, 3, 4, 5, 6, 7, 8
    • adverse event and participant adverse event: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • adverse event and primary efficacy endpoint: 1, 2, 3, 4, 5
    • adverse event and seasonal influenza: 1, 2, 3, 4
    • adverse event and symptom score: 1, 2, 3, 4, 5
    • adverse event and treatment end: 1, 2, 3, 4, 5, 6, 7
    • adverse event and viral load: 1, 2, 3, 4, 5, 6
    • available:1 0:day and cgeq ml: 1
    • available:1 0:day and efficacy endpoint: 1
    • available:1 0:day and neuraminidase inhibitor: 1
    • available:1 0:day and primary efficacy endpoint: 1
    • available:1 0:day and seasonal influenza: 1
    • available:1 0:day and symptom alleviation: 1
    • available:1 0:day and treatment end: 1
    • available:1 0:day and virological effect: 1
    • cgeq ml and efficacy endpoint: 1
    • cgeq ml and illness resolution: 1
    • cgeq ml and primary efficacy endpoint: 1